SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Novo Nordisk A/S on behalf of investors who acquired the company's securities between May 7, 2025, and July 28, 2025, alleging misrepresentations regarding the growth potential of its diabetes/obesity drug, GLP-1 [1][3]. Group 1 - The lawsuit claims that the defendants made misrepresentations about Novo's growth potential related to its diabetes/obesity drug, GLP-1 [3]. - The deadline for potential lead plaintiffs to file papers is September 30, 2025 [4]. - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its success in litigating class actions [5].